The prevalence of fertility complications is on the rise worldwide. In 2013, the Centers for Control of Disease and Prevention (CDC) estimated that the number of women with fertility complications would increase from 68 million in 2010 to 72 million by 2017 globally. Many women prefer to undergo pregnancy after the age of 35 years. Therefore, the percentage of first births among women aged above 35 years increased globally from 5% in 1975 to 23% in 2010. As the human body undergoes various hormonal and physiological changes with age, nearly 35% women aged above 35 face risks of fertility complications. The likelihood of such complications further increases due to obesity in both males and females. It causes hormonal imbalance in men, which can reduce their sperm count and lower their libido.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 06: Market segmentation by under-lying cause

PART 07: Market segmentation by technique

PART 08: Market segmentation by end-user

Market overview

Fertility clinics

Hospitals and research institutes

PART 09: Geographical segmentation

Market overview

Male infertility market in Americas

Male infertility market in EMEA

Male infertility market in APAC

PART 10: Decision framework

Market Drivers

Impact of drivers on key customer segments

Market challenges

Impact of challenges on key customer segments

PART 11: Market trends

PART 12: Vendor landscape

Competitive scenario

PART 13: Key Vendor Analysis

ASKA Pharmaceutical

Halotech DNA

Merck Serono

Zydus Cadila Healthcare

Other prominent vendors

PART 14: Appendix

List of abbreviations

PART 15: Explore Technavio